Navigation Links
Rockefeller University's Center for Clinical and Translational Science funds pilot studies
Date:1/7/2008

The Rockefeller University Center for Clinical and Translational Science (CCTS) has announced the recipients of its 2008 Pilot Project grants. Eight Rockefeller researchers will each receive $25,000 from the center to fund early studies in translational science that, if successful, might lead to clinical trials. The CCTS and the grant program are in their second year, established through funds from a Clinical and Translational Science Award the university received from the National Center for Research Resources of the National Institutes of Health. In its first year, the program provided $165,000 for nine clinical studies.

The centers administration selected the 2008 pilot projects from among proposals submitted in the fall. The recipients are:

  • Marina Caskey, an instructor in clinical investigation, to compare the efficacy of poly IC and Ampligen as adjuvants for an HIV vaccine targeted at DEC-205, an antigen receptor on dendritic cells.

  • Delivette Castor, instructor in clinical investigation, to apply demographic, psychosocial, sexual and drug use history and other data gathered from 280 men who have sex with men to examine the roles of these factors in the risk of HIV-1 infection and transmitted drug resistance.

  • Mouquet Hugo, postdoctoral fellow in Michel Nussenzweigs Laboratory of Molecular Immunology, to elucidate the etiology of Pemphigus vulgaris, a life-threatening autoimmune disease affecting skin and mucosa, by comparing repertoires of autoreactive and polyreactive B cells in patients with the disease to those of healthy volunteers.

  • Igor Kravets, instructor in clinical investigation, to examine the mechanism of action of disulfiram, a drug commonly used to treat chronic alcoholism, with regard to cocaine addiction.

  • Jan Lunemann, postdoctoral fellow in Christian Mnzs Laboratory of Viral Immunobiology, to test the hypothesis that a cause of multiple sclerosis is an aberrant response of the central nervous system to the Epstein Barr virus on the level of virus-infected B cells.

  • Lisa Neff, instructor in clinical investigation, to test the hypothesis that the Dietary Approaches to Stop Hypertension diet and the low glycemic index diet improve insulin sensitivity in patients with insulin resistance and/or metabolic syndrome.

  • Swaroop Pendyala, instructor in clinical investigation, to determine if significant weight loss achieved by dieting decreases chronic inflammation in the colorectal epithelium and reduces fecal calprotectin levels.

  • Alexander Ploss, postdoctoral associate in Charles Rices Laboratory of Virology and Infectious Disease, to generate patient-specific human hepatocytes as a renewable source for primary liver tissue.


'/>"/>

Contact: Joseph Bonner
bonnerj@rockefeller.edu
212-327-8998
Rockefeller University
Source:Eurekalert

Related medicine news :

1. National Patient Advocate Foundation Hails Senator Rockefeller for Introducing Bill Protecting Patient Access to Health Coverage
2. Columbia Center for Childrens Environmental Health receives NIEHS grant to study asthma
3. Parkway Clinical Laboratories Expands Management Team to Support a National Growth Strategy Centered on Oral Fluid Drug Screening
4. Susan G. Komen for the Cure, Ryan Community Health Centers, Breast Cancer Survivors Call on New York State to Expand Breast Cancer Screening, Treatment Programs
5. Language centers revealed, brain surgery refined with new mapping
6. Brown named Center of Excellence in Geriatric Medicine and Training
7. American College of Physicians receives grant to study cost of patient-centered medical home
8. Americas Blood Centers Thanks Donors During Celebration of National Blood Donor Month
9. Grubb & Ellis Healthcare REIT Acquires Chesterfield Rehabilitation Center in Chesterfield, Missouri in a Joint Venture with Duke Realty
10. Fitworks West Chester Mega-Center Now Open
11. National Drug Intelligence Center Releases 2008 National Methamphetamine Threat Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
(Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
(Date:2/5/2016)... ... 2016 , ... At its annual meeting held last week, the American Parkinson ... Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are ... , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a web theme ... to the next using Colorize's dynamic moving camera. Colorize is perfect for personal and ... 3D slideshow environment with 1 to 5 focus points per scene, stage floor scene ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... Ind. , Feb. 5, 2016  Zimmer Biomet ... pricing of the previously announced underwritten secondary offering of ... its stockholders, consisting of affiliates of Blackstone and Goldman ... at an initial price of $96.45 per share. The ... the offering.  Neither Zimmer Biomet nor any of its ...
Breaking Medicine Technology: